Alcanza Clinical Research Expands Network Through Strategic Acquisition of CNS Healthcare

GTTP

Alcanza acquires CNS Healthcare to bolster its multispecialty clinical trial site network.
The merger adds five key research locations and a mobile clinical unit to Alcanza's footprint.
The deal advances the 'Clinical Research for All™' initiative by increasing access in diverse communities.
Combined entity now operates over 30 research sites across the United States and Puerto Rico.

Impact - Why it Matters

This acquisition significantly scales Alcanza’s clinical trial footprint, merging specialized neuroscience expertise with a robust, community-focused infrastructure. By consolidating these high-performing sites, the merger accelerates the delivery of inclusive, high-quality clinical data, ultimately shortening timelines for life-changing therapies while addressing critical gaps in patient representation within the global research ecosystem.

Summary

Alcanza Clinical Research has officially announced the acquisition of CNS Healthcare, a prominent independent clinical research network with a distinguished thirty-year history. Since its founding in 1996, CNS Healthcare has established a reputation for excellence in neuroscience and behavioral health, managing thousands of clinical trials across five strategic locations in Tennessee and Florida, alongside a mobile research unit.

This partnership aligns two organizations dedicated to high-quality data and patient-centric trial execution. Under the leadership of CEO Dan Kearney, CNS Healthcare brings an experienced team of principal investigators and a legacy of consistent site performance. This integration strengthens Alcanza's multispecialty capabilities, allowing the combined entity to leverage deeper expertise and broader reach to meet the evolving needs of global pharmaceutical sponsors.

The acquisition serves to accelerate Alcanza’s mission, Clinical Research for All™, by expanding its footprint into diverse communities. With a combined network now exceeding 30 dedicated research units across the United States and Puerto Rico, the organization is uniquely positioned to improve representation in clinical trials. This move underscores a shared commitment to inclusive patient engagement and the delivery of life-changing therapeutic advancements to under-represented populations.

Alcanza Clinical Research Expands Network Through Strategic Acquisition of CNS Healthcare

GTTP

Alcanza acquires CNS Healthcare to bolster its multispecialty clinical trial site network.
The merger adds five key research locations and a mobile clinical unit to Alcanza's footprint.
The deal advances the 'Clinical Research for All™' initiative by increasing access in diverse communities.
Combined entity now operates over 30 research sites across the United States and Puerto Rico.